Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO) is a molecular diagnostics company focused on AI-powered cardiovascular disease detection, formed through a business combination with Executive Network Partnering Corporation, a blank-check company whose IPO priced in 2021 and whose sponsor was Executive Network Partnering Corp. Sponsor LLC. The merger closed in 2022, bringing Cardio Diagnostics into the public markets under the CDIO ticker. The company operates in the healthcare diagnostics sector, developing epigenetic testing products designed to assess cardiovascular disease risk. The 10-Q filed August 10, 2022 captures the company's initial post-combination operating period as a standalone public entity. Visit SpacDesk and sign up for full filings, sponsor profiles, and deal analytics on CDIO and hundreds of other SPAC transactions.